

## Overview of key LEN dose, volumes, timelines and prices

April 2026

<a href="#">Dose (excluding the 4-pill loading dose at initiation)</a>	Every six months
Number of vials per dose	2
Number of injectable doses for a year of protection	2
Number of injectable vials for a year of protection	4
Gilead's statement of annual LMIC production IF ordered	10 million vials
Gilead's statement of annual LMIC production IF ordered	2.5 million person years <u>per year</u> (PPPY)
<a href="#">Global Fund/PEPFAR commitment (Dec 2024) for 2026-2028</a>	2 million person years <u>over 3 years</u>
<a href="#">Possible LEN market in early adopter countries in 2026</a>	1,500,000 person years
Global Fund/PEPFAR orders for 2026 (from Gilead)	600,000 person years
Global Fund/PEPFAR to order for 2027/28 (Gilead & generics)	1,400,000 person years
Gilead's stated lead-time for manufacturing	6-9 months
Generic lead-time for manufacturing	Unclear – possibly less than Gilead
<a href="#">Initial generic approvals (from at least two manufacturers)</a>	Expected by mid-2027
<a href="#">Price from Gilead to Global Fund</a>	Confidential; rumored \$100 PPPY
Amount Global Fund asked countries to budget for supply	\$60 PPPY
<a href="#">Price from initial generics</a>	\$55 PPPY to initiate; \$40 PPPY ongoing

- It is not clear if Gilead can make any additional product for delivery in 2026, given the lead-time for manufacturing.
- Orders for 2027 for both Gilead and for generics needs to happen now to ensure deliveries are made to ensure uninterrupted supply for both continued effective use for those who want to remain on LEN, as well as anticipated (and necessary) market growth to deliver impact.

More on LEN at <https://avac.org/lenacapavir/> and <https://www.prepwatch.org/products/lenacapavir-for-prep/>.